Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab PK/Safety in Healthy Chinese Subjects
NCT03928262Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of benralizumab in eosinophilic asthma (EA) (3 arms), sponsored by AstraZeneca. Primary endpoints: Number of subjects with Adverse events (AEs) and serious adverse events (SAEs), Safety as determined by abnormality in haematology, clinical chemistry, and urinalysis and 2 more. Started Apr 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03928262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928262.